REATA PHARMACEUTICALS INC
RETA evidence brief
What we can confirm
- BioSniper Score:
- 7.2 / 10
- Lead Asset:
- bardoxolone (Phase 3)
What it means
What to watch
Prepared research question
What matters most for RETA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
bardoxolone (Phase 3)
Next Catalyst
—
Tracking 3 pipeline candidates for REATA PHARMACEUTICALS INC.
Run REATA PHARMACEUTICALS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available REATA PHARMACEUTICALS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is REATA PHARMACEUTICALS INC's lead drug candidate?
REATA PHARMACEUTICALS INC's most advanced tracked candidate is bardoxolone (Phase 3) for Chronic kidney disease (CKD) caused by Alport syndrome, autosomal dominant polycystic kidney disease (ADPKD), and type 1 and 2 diabetic CKD.
Who is the CEO of REATA PHARMACEUTICALS INC?
Warren Huff is the chief executive officer of REATA PHARMACEUTICALS INC (RETA).
What therapeutic areas does REATA PHARMACEUTICALS INC focus on?
REATA PHARMACEUTICALS INC develops therapies across Neurology, Pain, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.